PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCER
Keyword(s):
Keyword(s):
2014 ◽
Vol 90
(1)
◽
pp. S589
Cost–effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer
2020 ◽
Vol 9
(18)
◽
pp. 1301-1309
Keyword(s):
The Cost
◽
2021 ◽
pp. 1-13
Keyword(s):
2019 ◽
Vol Volume 11
◽
pp. 9195-9202
◽
Keyword(s):
Keyword(s):